The table provided is a review of notable updates that occurred in January 2023 for investigational products in development.
Olezarsen is an investigational LICA antisense medication designed to inhibit the production of apoC-III for patients at risk of disease due to elevated triglyceride levels.
But polypill with or without aspirin is associated with reduced functional decline for those aged 65 years or older with cardiovascular risk factors
19.05 million deaths estimated for CVD globally in 2020, representing an increase of 18.71 percent from 2010
Current evidence is inadequate for assessing the balance of benefits and harms of screening in a pediatric population
Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
The application is supported by data from the phase 3 EMPA-KIDNEY trial, which enrolled more than 6600 adults with CKD at risk of kidney disease progression.
At what point does a patient become liable for their own injury when medical advice is not followed?